hearing-sonion-aid-19.html
Novo Annual Report 2015
20 / 72
c hr.
hansen
is a global bioscience company with leadership positions in a number of attractive niche markets, including cultures for the food & beverage, human health, animal health and plant protection industries; enzymes for the dairy industry; and natural colours for the food & beverage industry. chr
. hansen?s solutions offer an attractive cost-to-value ratio for customers. the company has a strong r&d development platform, core capabilities in large- scale fermentation of cultures and strong application know how ? all of which ensures successful integration with customers? products and processes. chr. hansen?s nature?s no. 1 strategy continues to guide the long-term direction of the company, and good progress in the strategic initiatives has been seen ? both in established businesses and in new
initiatives within biological plant protection and the human microbiome. moreover, chr. hansen has taken an important step in its strategic venture into new generations of probiotic products and therapeutic microbes. chr. hansen founded in 1874 in copenhagen, denmark headquartered in hørsholm, denmark with development centres in denmark, the us, france and germany major investors include novo a/s (from 2012), capital group companies and apg asset management n.v. revenue in 2014/15: eur 859 million public company listed on nasdaq omx copenhagen since 2010. code chr www.chr-hansen.com news launched a new generation of capcolors ® orange that enables conversion to stable and non-artificial colouration in the beverage market. launched the direct vat set ® solution, dvs ® whiteclassic culture, designed to match greek feta?s balanced round flavours and creamy texture, while ensuring consistency and control. søren westh lonning was appointed new cfo. novo a/s 20 large investments
novo-company-symphogen-21.html
